Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ionis Pharmaceutical (IONS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,869,779
  • Shares Outstanding, K 138,398
  • Annual Sales, $ 599,670 K
  • Annual Income, $ 273,740 K
  • 60-Month Beta 2.40
  • Price/Sales 17.87
  • Price/Cash Flow 24.20
  • Price/Book 8.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.56
  • Number of Estimates 6
  • High Estimate 1.05
  • Low Estimate -0.39
  • Prior Year -0.01
  • Growth Rate Est. (year over year) +5,700.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.98 +37.45%
on 02/21/19
79.72 -1.76%
on 03/18/19
+19.34 (+32.79%)
since 02/15/19
3-Month
48.27 +62.25%
on 12/24/18
79.72 -1.76%
on 03/18/19
+27.05 (+52.76%)
since 12/18/18
52-Week
39.07 +100.46%
on 05/08/18
79.72 -1.76%
on 03/18/19
+26.63 (+51.52%)
since 03/16/18

Most Recent Stories

More News
Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)

Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that data from the NEURO-TTR open-label extension study...

AKCA : 29.77 (-0.80%)
IONS : 78.51 (-0.04%)
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences:

IONS : 78.51 (-0.04%)
PTC to Expand Product Portfolio in Latin America with WAYLIVRA(TM)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its partner, Akcea Therapeutics, affiliate of Ionis Pharmaceuticals, received a positive opinion for WAYLIVRA(TM) by the Committee for Medicinal...

PTCT : 36.91 (+2.10%)
IONS : 78.51 (-0.04%)
Detailed Research: Economic Perspectives on Huntsman, eHealth, Ionis Pharmaceuticals, Arch Capital Group, Copart, and Acorda Therapeutics -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Huntsman Corporation (NYSE:HUN),...

HUN : 22.51 (-2.72%)
CPRT : 58.98 (-0.08%)
EHTH : 58.61 (-1.20%)
IONS : 78.51 (-0.04%)
ACGL : 32.73 (-0.43%)
ACOR : 14.43 (-1.37%)
Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)

Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Committee for Medicinal Products for Human...

AKCA : 29.77 (-0.80%)
IONS : 78.51 (-0.04%)
Ionis Pharmaceut Up 33.0% Since SmarTrend Uptrend Call (IONS)

SmarTrend identified an Uptrend for Ionis Pharmaceut (NASDAQ:IONS) on January 2nd, 2019 at $53.35. In approximately 2 months, Ionis Pharmaceut has returned 32.97% as of today's recent price of $70.94....

IONS : 78.51 (-0.04%)
Biogen Further Expands Presence in China with Approval of SPINRAZA(R) (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy

SPINRAZA is the standard of care for treating infants, children and adults with spinal muscular atrophy, a rare, genetic neuromuscular disease

IONS : 78.51 (-0.04%)
BIIB : 325.10 (-1.45%)
Akcea(R) Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome

Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced the...

AKCA : 29.77 (-0.80%)
IONS : 78.51 (-0.04%)
Ionis Exceeds 2018 Financial Guidance

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the fourth quarter and full year 2018 and reviewed highlights of its successful year.

IONS : 78.51 (-0.04%)
Novartis In-Licenses Rights to Heart Candidate From Ionis

Novartis (NVS) in-licenses rights to develop and commercialize TQJ230 from Ionis Pharmaceuticals for treating targeted cardiovascular diseases.

IONS : 78.51 (-0.04%)
NVS : 93.00 (-0.31%)
GSK : 40.49 (-0.34%)
BIIB : 325.10 (-1.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade IONS with:

Business Summary

Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California.

See More

Key Turning Points

2nd Resistance Point 79.69
1st Resistance Point 79.12
Last Price 78.51
1st Support Level 77.44
2nd Support Level 76.33

See More

52-Week High 79.72
Last Price 78.51
Fibonacci 61.8% 64.19
Fibonacci 50% 59.40
Fibonacci 38.2% 54.60
52-Week Low 39.07

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar